EPISODE · Dec 17, 2025 · 2 MIN
UK Pharma Wins Tariff Exemption in US Trade Deal, Faces Broader Import Challenges Under Trump Agreements
from United Kingdom Tariff News and Tracker · host Inception Point AI
Welcome to United Kingdom Tariff News and Tracker, your essential guide to the latest US trade developments affecting UK businesses under President Trump. In a major win for the UK life sciences sector, the US and UK have struck a landmark agreement in principle on pharmaceuticals and medtech, as detailed by Mills & Reeve and AFS Law. UK-origin medicines, pharmaceutical ingredients, and medical technology are now exempt from US tariffs for at least three years, shielding them from Section 232 duties. In exchange, the UK commits to boosting spending on innovative treatments by 25%, with NICE raising its cost-effectiveness threshold from £20,000-£30,000 to £25,000-£35,000 per QALY gained. This could greenlight 3-5 more new medicines annually. Plus, the Voluntary Scheme for Branded Medicines Pricing and Access payment rate drops to 14.5% in 2026 from 22.9% in 2025, easing pressures on pharma firms. Broader tariffs pose challenges, though. The Manufacturer reports the UK faces a general 10% US tariff on imports, part of Trump's sweeping hikes now averaging 17.9% per Yale's Budget Lab analysis cited by Freiheit.org. EY Tax News notes some tariffs start at zero percent on January 1, 2026, rising to 10% in 2027 and 15% in 2028. AFS Law highlights exemptions for UK pharma amid Section 301 extensions through November 2026, but UK exporters must navigate rising shipping and customs costs, as warned by Power Forwarding. A snag: Alliance News reports the US has suspended implementation of a UK tech cooperation deal on December 16, signaling tensions in other sectors. These moves stem from the May 2025 UK-US Economic Prosperity Deal, balancing tariff relief with pricing reforms. UK firms in pharma and medtech gain a lifeline, but manufacturers watch general rates warily amid Trump's reciprocal tariff push. Thanks for tuning in, listeners—subscribe now for weekly updates to stay ahead. This has been a Quiet Please production, for more check out quietplease.ai. For more check out https://www.quietperiodplease.com/ Avoid ths tariff fee's and check out these deals https://amzn.to/4iaM94Q This content was created in partnership and with the help of Artificial Intelligence AI.
What this episode covers
Welcome to United Kingdom Tariff News and Tracker, your essential guide to the latest US trade developments affecting UK businesses under President Trump. In a major win for the UK life sciences sector, the US and UK have struck a landmark agreement in principle on pharmaceuticals and medtech, as detailed by Mills & Reeve and AFS Law. UK-origin medicines, pharmaceutical ingredients, and medical technology are now exempt from US tariffs for at least three years, shielding them from Section 232 duties. In exchange, the UK commits to boosting spending on innovative treatments by 25%, with NICE raising its cost-effectiveness threshold from £20,000-£30,000 to £25,000-£35,000 per QALY gained. This could greenlight 3-5 more new medicines annually. Plus, the Voluntary Scheme for Branded Medicines Pricing and Access payment rate drops to 14.5% in 2026 from 22.9% in 2025, easing pressures on pharma firms. Broader tariffs pose challenges, though. The Manufacturer reports the UK faces a general 10% US tariff on imports, part of Trump's sweeping hikes now averaging 17.9% per Yale's Budget Lab analysis cited by Freiheit.org. EY Tax News notes some tariffs start at zero percent on January 1, 2026, rising to 10% in 2027 and 15% in 2028. AFS Law highlights exemptions for UK pharma amid Section 301 extensions through November 2026, but UK exporters must navigate rising shipping and customs costs, as warned by Power Forwarding. A snag: Alliance News reports the US has suspended implementation of a UK tech cooperation deal on December 16, signaling tensions in other sectors. These moves stem from the May 2025 UK-US Economic Prosperity Deal, balancing tariff relief with pricing reforms. UK firms in pharma and medtech gain a lifeline, but manufacturers watch general rates warily amid Trump's reciprocal tariff push. Thanks for tuning in, listeners—subscribe now for weekly updates to stay ahead. This has been a Quiet Please production, for more check out quietplease.ai. For more check out https://www.quietperiodplease.com/ Avoid ths tariff fee's and check out these deals https://amzn.to/4iaM94Q This content was created in partnership and with the help of Artificial Intelligence AI.
NOW PLAYING
UK Pharma Wins Tariff Exemption in US Trade Deal, Faces Broader Import Challenges Under Trump Agreements
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m